8,272 Shares in BioNTech SE (NASDAQ:BNTX) Acquired by Crestline Management LP

Crestline Management LP bought a new position in BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 8,272 shares of the company's stock, valued at approximately $943,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp lifted its position in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after buying an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. raised its holdings in shares of BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE bought a new position in BioNTech in the 4th quarter worth $90,000. GAMMA Investing LLC raised its holdings in BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company's stock worth $105,000 after acquiring an additional 300 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. bought a new position in BioNTech in the 4th quarter worth $137,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Price Performance

Shares of BNTX stock traded up $0.37 during trading hours on Thursday, reaching $92.46. 546,383 shares of the company were exchanged, compared to its average volume of 924,973. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock's fifty day moving average is $97.78 and its two-hundred day moving average is $109.17. The company has a market cap of $22.23 billion, a price-to-earnings ratio of -44.12 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the prior year, the business earned $1.90 earnings per share. BioNTech's quarterly revenue was down 19.5% on a year-over-year basis. Sell-side analysts forecast that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BNTX has been the topic of several research analyst reports. Morgan Stanley decreased their price target on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and issued a $134.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Wednesday. BMO Capital Markets upped their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Citigroup reissued a "buy" rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $142.08.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.